Evaluating AI in Healthcare: Implementing Approaches
By Sumona Bose
March 7, 2024
Introduction
Artificial intelligence (AI) holds great potential in healthcare by enhancing clinical decision-making and patient outcomes. However, a significant gap exists between the development of AI models and their successful integration into clinical practice. Despite the proliferation of AI-based clinical decision support systems (AICDSS), only a meager 2% of these models progress beyond the prototyping stage, leaving the actual clinical impact largely unexplored.
Evaluating Clinical Value through Rigorous Trials
The evaluation of AICDSS through randomised controlled trials (RCTs) stands as a critical step in determining their true clinical value. While some RCTs have been conducted, their outcomes paint a nuanced picture. Although these trials showcase promising statistical performance of AI, nearly half of them fail to demonstrate improved patient outcomes. This discrepancy underscores the complexity of assessing AI solely based on quantitative metrics like accuracy. This may not capture the practical utility of these systems in real-world healthcare settings. Table 1 unpacks the definitions associated with interpreting the patient outcomes. This helps clinicians and researchers shift from the arbitrariness that hinders real-world settings.
Reported in N (%)
Implementation outcomea
Clinical explanation
Implementation stage
RCTs (N = 64)
Guidelinesb (N = 5)
Appropriateness
Is the AI compatible with the clinical workflow and is it useful?
Early
5 (8)
0 (0)
Acceptability
Is the AI acceptable, agreeable, or satisfactory for the users?
Ongoing
10 (16)
0 (0)
Feasibility
Can the AI be successfully used as intended by the manufacturer?
Early
16 (25)
0 (0)
Adoption
Do the users express the initial decision, or action to try or employ the AI?
Ongoing
6 (9)
0 (0)
Fidelity
Is the AI implemented as intended by the manufacturer?
Ongoing
31 (48)
0 (0)
Implementation cost
What is the cost impact of implementing the AI system?
Late
4 (6)
0 (0)
Penetration
Has the AI been adopted by all groups of trained users?
Late
0 (0)
0 (0)
Sustainability
Is the AI maintained within ongoing clinical operations over time?
Late
1 (2)
0 (0)
Table 1: AI in RCTs, Definitions of implementation outcomes were adapted from the taxonomy of implementation outcomes by Proctor et al (2011).
The Need for a Holistic Evaluation Approach
A comprehensive understanding of AI’s role in clinical practice necessitates a multi-faceted evaluation strategy. Current guidelines like Developmental and Exploratory Clinical Investigations of DEcision support systems driven by Artificial Intelligence (DECIDE-AI) and Consolidated Standards of Reporting Trials–Artificial Intelligence (CONSORT-AI), fall short in providing robust measures for assessing AI implementation success. To address this gap, a mixed-methods evaluation approach, proves invaluable in dissecting the various dimensions of AICDSS implementation.
Bridging the Gap in Implementation Evaluation
Despite the increasing focus on RCTs evaluating AICDSS in clinical settings, a gap exists in the comprehensive evaluation of implementation outcomes. While metrics like ‘fidelity’ are commonly reported using quantitative measures, aspects such as ‘acceptability’ and ‘appropriateness’ that demand qualitative scrutiny are often overlooked. This imbalance underscores the need for a more holistic approach towards evaluating the implementation of AICDSS, encompassing factors beyond statistical performance. Figure 1 reiterates the comprehensive value of integrating implementation outcomes in AI in healthcare, revealing an innovative future in the field.
Conclusion
While the efficacy of AICDSS in healthcare settings is crucial, understanding the contextual nuances is imperative. Enhanced systematic reporting of implementation outcomes alongside effectiveness metrics can bridge the existing gap in comprehensively assessing the impact of clinical AI. Embracing an inclusive evaluation framework will not only validate the effectiveness of AICDSS but also shed light on the intricate interplay between AI technology and healthcare delivery.
💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?
A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.
With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.
Explore the details of this impactful collaboration and how it could transform HIV prevention.
🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?
With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.
The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.
Discover the pressing challenges and potential solutions in our latest article.
🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟
Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.
This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.
Read more about BioSapien’s journey and its impact on global health!
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.